Press Releases

Stay informed about the newest developments at Genescopy and explore how we are revolutionizing gastrointestinal health.

Geneoscopy’s Dr. Erica Barnell to Present at Women @ Work Summit and American Gastroenterological Association (AGA) Workshop

November 7, 2024

Geneoscopy Receives New York State Department of Health Permit, Expanding Ability to Provide Laboratory Services Nationwide

October 1, 2024

Geneoscopy to Present at Gastroenterology and Cancer Surveillance Conferences, Highlighting Advancements in Colorectal Cancer Screening and Early Detection

August 14, 2024

Geneoscopy’s CEO Andrew Barnell to Present at Upcoming Investor Conferences

August 8, 2024

Geneoscopy’s Novel Stool-Based RNA Platform Shows High Accuracy in Monitoring Crohn’s Disease

August 1, 2024

U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy’s Petition Challenging Validity of ‘781 Patent Owned by Exact Sciences

July 29, 2024

Peer-Reviewed Study Confirms Reliability of ColoSense, Geneoscopy’s Noninvasive Multi-target Stool RNA Colorectal Cancer Screening Test

July 10, 2024

Geneoscopy Files Counterclaims Against Exact Sciences

July 1, 2024

Geneoscopy Advances Mission to Transform Gastrointestinal Health at Digestive Disease Week 2024

May 24, 2024

Court Dismisses Exact Sciences’ ‘781 Patent Infringement Claim Against Geneoscopy

May 22, 2024

Geneoscopy Expands Leadership Team to Support ColoSense™ Rollout and Advance Precision IBD Solution

May 15, 2024

FDA Approves ColoSense™ – Geneoscopy’s Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

May 6, 2024

Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference

April 3, 2024

Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)

January 17, 2024

Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent

January 12, 2024

Geneoscopy and Adiso Therapeutics Announce Strategic Collaboration to Investigate New Therapeutic Options for Patients with Inflammatory Bowel Disease

December 5, 2023

Geneoscopy Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

November 14, 2023

Don Hardison Appointed Chairman of the Board at Geneoscopy

November 9, 2023

JAMA Publishes Geneoscopy’s Pivotal CRC-PREVENT Trial Results, Reporting Highest Sensitivity for Detecting Colorectal Cancer and Advanced Adenomas Among Available Noninvasive Screening Tests

October 23, 2023

Geneoscopy to Present and Exhibit at American College of Gastroenterology 2023 Annual Meeting

October 5, 2023

Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 6, 2023

Geneoscopy Joins White House for Cancer Moonshot Colorectal Cancer Forum

March 10, 2023

Geneoscopy appoints Don Hardison to its Board of Directors

February 28, 2023

Geneoscopy Submits Premarket Approval Application to FDA for its Noninvasive Colorectal Cancer RNA Biomarker Screening Test

January 24, 2023

Geneoscopy’s Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial

January 10, 2023

Geneoscopy announces rebranding

October 4, 2022

Geneoscopy Completes Pivotal Colorectal Cancer Trial Enrollment with Diverse Participant Population

September 27, 2022

Geneoscopy to Join Fight CRC at the White House to Address Colorectal Cancer Screening Needs

July 19, 2022

Geneoscopy Announces Formation of Scientific Advisory Board to Inform Strategy for the Advancement of Gastrointestinal Health

June 21, 2022

Geneoscopy Cost-Effectiveness Modeling Data Demonstrates Potential to Reduce Colorectal Cancer Cases and Deaths in the United States with RNA-FIT Screening Test

May 23, 2022

Geneoscopy Tackles Healthcare Disparities in Pivotal Colorectal Cancer Clinical Trial Utilizing a Digital Recruitment Strategy

January 20, 2022

Geneoscopy Announces Positive Results of Colorectal Cancer Screening Test in Prospective, Multicenter Clinical Study

November 19, 2021

Geneoscopy Closes $105M in Financing to Advance its Noninvasive Multifactor RNA Screening Test for Colorectal Cancer Prevention

November 16, 2021

Geneoscopy Appoints Dr. Haytham Gareer as Chief Medical Officer

October 18, 2021

Geneoscopy Honored by Goldman Sachs for Entrepreneurship

October 13, 2021

Geneoscopy Enrolls First Patients in CRC-PREVENT U.S. Pivotal Trial

July 12, 2021

Geneoscopy Announces Publication of Peer-Reviewed Article Highlighting Effective Noninvasive Screening Test for Colorectal Cancer Prevention

May 25, 2021

Geneoscopy Appoints Don Hardison to its Strategic Advisory Board

March 17, 2021

Geneoscopy Appoints Vince Wong as Chief Commercial Officer

March 3, 2021

Geneoscopy’s Preventive Screening Test for Colorectal Cancer and Precancerous Adenomas Earns FDA Breakthrough Device Designation

January 13, 2020

Geneoscopy Raises $6.9 Million to Advance Preventive Screening Test for Colorectal Cancer and Advanced Adenomas

October 2, 2019